| Abstract: | The notion that depression subtyping would sharpen the antidepressant treatment advantage over placebo has been around for years. This article questions whether the endogenous–neurotic distinction has proven useful by briefly surveying the evidence on diagnostic reliability and predictability of treatment response. The issue of subtyping is then related to data from the meta-analysis on antidepressant efficacy (see record 1993-06735-001). (PsycINFO Database Record (c) 2010 APA, all rights reserved) |
